{"pageContent": "Purpose of review: In recent clinical trials, immunotherapeutic agents have demonstrated promising results for the treatment of prostate cancer. This review discusses emerging immunotherapies for prostate cancer and their evolving role in sequencing and combination therapy.", "metaData": {"source": "BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/28410213/"}}